论文部分内容阅读
目的:探讨ER、PR、HER-2、p53、MDR-1、BCL-2表达对紫杉类药物治疗乳腺癌疗效的预测作用。方法:对136例接受紫杉类药物治疗的乳腺癌患者进行回顾性分析,采用免疫组织化学法检测生物学指标ER、PR、HER-2、p53、MDR-1、BCL-2的表达,并分析其与治疗效果的关系。结果:136例乳腺癌患者接受紫杉类药物治疗,总有效率为45.59%;单因素分析显示p53、MDR-1、BCL-2阴性与阳性表达的有效率差异均无统计学意义(P>0.05),ER、PR阴性表达与HER-2过表达的有效率明显高于ER、PR阳性表达与HER-2低表达(ER:χ2=11.051,P=0.008;PR:χ2=7.533,P=0.021;HER-2:χ2=12.395,P=0.002);多因素分析ER阴性表达与HER-2过表达具有统计学意义(ER:OR=0.172,P=0.004;HER-2:OR=3.407,P=0.003);进一步分析ER与HER-2不同表达搭配显示ER阴性与HER-2过表达的有效率高达86.21%,明显高于其他3种搭配(P=0.001),其余3种搭配间有效率无统计学差异(P>0.05)。结论:ER阴性表达及HER-2过表达可作为紫杉类药物治疗乳腺癌疗效的预测生物学指标。
Objective: To investigate the predictive value of ER, PR, HER-2, p53, MDR-1 and BCL-2 on the efficacy of taxanes in the treatment of breast cancer. Methods: A retrospective analysis was performed on 136 breast cancer patients treated with taxanes. The expression of biological markers ER, PR, HER-2, p53, MDR-1 and BCL-2 were detected by immunohistochemistry Analyze its relationship with the treatment effect. Results: The total effective rate was 45.59% in 136 cases of breast cancer patients treated with taxanes. Univariate analysis showed that there was no significant difference in the effective rates of negative expression of p53, MDR-1 and BCL-2 (P> 0.05). The rates of ER, PR negative expression and HER-2 overexpression were significantly higher than those of ER, PR positive expression and HER-2 low expression (ER: χ2 = 11.051, P = 0.008; (OR = 0.172, P = 0.004; HER-2: OR = 3.407, P = 0.002). The positive rates of HER-2 and HER- P = 0.003); Further analysis of ER and HER-2 expression with ER negative and HER-2 overexpression was as high as 86.21%, significantly higher than the other three (P = 0.001), the other three with No significant difference in efficiency (P> 0.05). Conclusion: The negative expression of ER and the overexpression of HER-2 may be used as predictors for the efficacy of taxane in the treatment of breast cancer.